Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,584,309
  • Shares Outstanding, K 152,849
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,580 K
  • 60-Month Beta 0.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.46
Trade IOVA with:

Options Overview

Details
  • Implied Volatility 75.34%
  • Historical Volatility 196.79%
  • IV Percentile 56%
  • IV Rank 28.11%
  • IV High 122.38% on 05/19/21
  • IV Low 56.95% on 01/19/21
  • Put/Call Vol Ratio 0.55
  • Today's Volume 2,742
  • Volume Avg (30-Day) 8,300
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 89,070
  • Open Int (30-Day) 75,150

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.52
  • Number of Estimates 8
  • High Estimate -0.50
  • Low Estimate -0.53
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -10.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.88 +47.67%
on 05/19/21
27.76 -15.53%
on 05/18/21
-3.06 (-11.54%)
since 05/11/21
3-Month
15.88 +47.67%
on 05/19/21
35.72 -34.35%
on 03/16/21
-12.11 (-34.06%)
since 03/11/21
52-Week
15.88 +47.67%
on 05/19/21
54.21 -56.74%
on 01/15/21
-6.17 (-20.83%)
since 06/11/20

Most Recent Stories

More News
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study

IOVA : 23.45 (+1.34%)
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting

86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naive Advanced Melanoma Patients in IOV-COM-202 Clinical Study

IOVA : 23.45 (+1.34%)
Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the...

IOVA : 23.45 (+1.34%)
ALPN : 8.81 (-1.89%)
Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following...

IOVA : 23.45 (+1.34%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics (IOVA) Investors With Losses and Persons Who May Assist Firm's Investigation Into Possible Securities Law Violations to Contact Its Attorneys Now

, /PRNewswire/ -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to . The firm is investigating possible securities law violations and certain investors...

IOVA : 23.45 (+1.34%)
Ademi LLP Investigates Claims of Securities Fraud against Iovance Biotherapeutics, Inc.

, /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA).  The investigation results from inaccurate statements Iovance may have made regarding its...

IOVA : 23.45 (+1.34%)
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

RGEN : 191.52 (+0.80%)
BLPH : 4.71 (+3.06%)
IOVA : 23.45 (+1.34%)
BNTX : 238.55 (-0.53%)
Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

IOVA : 23.45 (+1.34%)
The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) on behalf of investors concerning the Company's possible violations...

IOVA : 23.45 (+1.34%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics (IOVA) Investors With Losses and Persons Who May Assist Firm's Investigation Into Possible Securities Law Violations to Contact Its Attorneys Now

Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors...

IOVA : 23.45 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

3rd Resistance Point 25.48
2nd Resistance Point 24.52
1st Resistance Point 23.98
Last Price 23.45
1st Support Level 22.48
2nd Support Level 21.52
3rd Support Level 20.98

See More

52-Week High 54.21
Fibonacci 61.8% 39.57
Fibonacci 50% 35.04
Fibonacci 38.2% 30.52
Last Price 23.45
52-Week Low 15.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar